Navigation Links
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
Date:6/30/2008

- Product appears safe with no dose-limiting toxicities -

- Chemophase dose for pivotal trials successfully determined - - Halozyme to seek input from regulatory authorities in order to advance

into pivotal clinical program in 2009 -

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a status update for its continuing Phase I/IIa Chemophase(R) clinical trial in the treatment of superficial bladder cancer. Based on the results, the Chemophase combination treatment of mitomycin plus the recombinant human hyaluronidase (rHuPH20) enzyme was well tolerated and appears safe. The study reported no dose-limiting toxicities and no observed side effects attributable to the enzyme, and established the dose for subsequent clinical trials, therefore achieving the pre-defined primary objective of the study. In addition, there were no neutralizing antibodies to rHuPH20 detected and the plasma concentration of mitomycin was either non-measureable or negligible and well below the threshold that may be predictive for myelosuppression (a decrease in bone marrow activity, resulting in fewer red blood cells, white blood cells, and platelets).

The study also provided support for future pivotal trial development that will incorporate the highest combination dose studied in the current trial, mitomycin plus 800,000 Units of rHuPH20. Commenting on the results, Richard C. Yocum, M.D., Vice President of Clinical Development and Medical Affairs at Halozyme stated, "We are pleased the study demonstrated that Chemophase was well-tolerated and produced no dose-limi
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
2. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
5. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
6. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
7. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
8. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
9. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
10. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
11. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... Nov. 25 The FDA granted tradition...ts, a non-nucleoside reverse transcriptase inhibit...ly indicated for use in treatment-experienced adul...-1 strains resistant to an NNRTI and other antiret... based on 48-week data from two Phase 3 studies kn...
(Date:11/25/2009)...alif., Nov. 25 AMPAC Fine Chemical...oration (Nasdaq: APFC ) announced today that it r...inability Award at the Annual Statewide Environmen...ers and Technology Association (CMTA), the Industr...al Industry Council of California (CICC) held in S...
(Date:11/25/2009)...ov. 25 Reportlinker.com announces ...its catalogue: ,, United States Dental Devices...p://www.reportlinker.com/p0158733/United-States-De....html ,, United States Dental Devices Market A..., This report is an essential source for in-depth ...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13LG Electronics Introduces New Flat Panel HDTVs Designed Specifically for Long Term Care Facilities 53486 1LG Electronics Introduces New Flat Panel HDTVs Designed Specifically for Long Term Care Facilities 53486 2LG Electronics Introduces New Flat Panel HDTVs Designed Specifically for Long Term Care Facilities 53486 3LG Electronics Introduces New Flat Panel HDTVs Designed Specifically for Long Term Care Facilities 53486 4COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 1COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 2Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 1Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 2
...Y HILLS, Mass., Aug. 25 Joseph F. Finn, Jr.,C.P.A...c. ("Spherics") for,the benefit of creditors, anno...roperty will be sold at a sealed bid auction on Oc...rmulation of Levodopa-Carbidopa that,is the curren... with global,sales estimated at approximately $250...
...ne CLL, NHL and CLL Retreatment and Japanese Devel...ned, COPENHAGEN, Denmark, August 25 Genmab has,a... in chronic lymphocytic,leukemia and non-Hodgkin,s... plans to begin four studies of,ofatumumab in chro...Hodgkin,s lymphoma (NHL) this year., "Genmab and ...
Other Medicine Technology:Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels 2Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4
(Date:11/27/2009)...s has announced that it has become a national spon...t nonprofit organizations dedicated to arthritis r... Delray Beach, FL (Vocus) November 27... company specializing in the marketing and retail ...announced today that is has become a national spon...
(Date:11/27/2009)...ade; announced today that Spectrum Health (Grand R...rise orthopedic templating solution and its Trauma... (PRWEB) November 27, 2009 -- Voyant Health&... Rapids, Michigan) has licensed its TraumaCad Ente...maCad Extend workflow solution, to allow its ortho...
(Date:11/26/2009)... -- With cold and flu season upon us, it,s more im...rol the spread of infections and avoid illness. ,...elves healthy, but to avoid transmitting illness i...ertified in infection-control), nursing director f...spital for Special Surgery (HSS) in Manhattan. ,...
(Date:11/26/2009)...ad to strains or worse , , THURSDAY, Nov...g with stuffing your turkey full to bursting, but ...suitcase as you pack for holiday trips. , More ...spital emergency rooms, doctors, offices, clinics ...njuries, such as muscle strains, pulls and tears, ...
(Date:11/26/2009)...e Dental (RTDental), a leading dental group practi...expansion of its services to include LUMINEERS by ... , Durham, NC (PRWEB) -...that Dr. Doug Macmillan, an experienced LUMINEERS...ed training seminar. RTDental’s ability to ...
Breaking Medicine News(10 mins):Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2
... , , WASHINGTON, March 23 Claire Franzen of Cent...y, March 29 through Tuesday, March 31, 2009 to mee...t for epilepsy public health programs and more res...ogram coordinated by the Epilepsy Foundation and f...
... F.A. Davis unveils DavisPT...at the APTA Combined Sections Meeting. The site fe... physical therapy continuing education courses (co... to announce the launch of DavisPTnetwork.com, a n...
... , , , , , WASHINGTON, March 23 David Rollick..., Sunday, March 29 through Tuesday, March 31, 2009... support for epilepsy public health programs and m...onal program coordinated by the Epilepsy Foundatio...
... PEMBROKE, Bermuda, March 23 Darwin National,As...Assurance Company,Holdings, Ltd (NYSE: AWH ), to...sident, Risk Management, will moderate a panel at ...n? Exploring the Risks,of Contaminated Medical Pro...
...Many people of East Asian descent possess an enzym...flush, when they drink alcohol. Scientists from t...ism (NIAAA) and Japan,s Kurihama Alcohol Center no...world,s population. Their review of recent researc...
... , , WASHINGTON, March 23 Alexandria Gray of Chi... March 29 through Tuesday, March 31, 2009 to meet ...for epilepsy public health programs and more resea...coordinated by the Epilepsy Foundation and funded ...
Other Medicine News:Health News:Colorado Youth Shares Epilepsy Message on Capitol Hill 2Health News:New Online Network Features Continuing Education Courses for Physical Therapists 2Health News:Virginia Youth Shares Epilepsy Message on Capitol Hill 2Health News:Darwin to Moderate Panel at Plus Medical Symposium 2Health News:Darwin to Moderate Panel at Plus Medical Symposium 3Health News:Alcohol 'flush' signals increased cancer risk among East Asians 2Health News:Alcohol 'flush' signals increased cancer risk among East Asians 3Health News:Illinois Youth Shares Epilepsy Message on Capitol Hill 2
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: